研究業績

• 1．SGSG-001 
  パクリタキセル抵抗性上皮性卵巣癌に対するドセタキセル隔週投与法の第I相および第II相試験
  IGCS 2002
  
  Oishi T, Kigawa J, Fujiwara K, Fujiwara M, Numa F, Aotani E, Katsumata N, Kohno I, Kato H, Terakawa N.
  A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer.
  Gynecol Oncol 2003: 90; 421-424.
  
• 2．SGSG-002
  卵巣癌に対するカルボプラチン腹腔内投与と静脈投与における薬理動態に関する研究
  
  日本癌治療学会 2002
  
  Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I.
  Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin- A Sankai Gynecology Study Group (SGSG) study
  Gynecol Oncol 2005: 99; 591-596.
• 3．SGSG-003
  上皮性卵巣癌に対するパクリタキセルとカルボプラチン併用化学療法におけるIP vs. IVの比較第III相試験
  
  ASCO 2004
  
  Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, Numa F, Okada M, Aotani E.
  Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Study Group Study
  Int J Gynecol Cancer 2009: 9; 834-837.
• 4. SGSG-004
  進行・再発子宮頸癌に対するドセタキセルとカルボプラチン併用療法の第II相試験
  
  ASCO 2006
  
  Takekida S, Fujiwara K, Nagao S, Yamaguchi S, Yoshida N, Kitada F, Kigawa J, Terakawa N, Nishimura R.
  Phase II study of combination chemitherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.
  Int J Gynecol Cancer 2010: 20; 1563-8.
• 5. SGSG-005
  子宮頸部非扁平上皮癌（Ib2-II期）に対する術前化学療法としてのドセタキセル＋カルボプラチン併用療法の有効性および安全性に関する検討（第II相試験）
  
  Shimada M, Nagao S, Fujiwara K, Takeshima N, Takizawa K, Shoji T, Sugiyama T, Yamaguchi S, Nishimura R, Kigawa J.
  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.
  Int J Clin Oncol 2016: 21; 1128-1135.
• 5a. SGSG-005付随研究
  Chemoresistance in gastric-type mucinous adenocarcinoma of the uterine cervix: Multi-institutional study by Sankai Gynecology Study Group (SGSG).
  Kojima A et al.
  ASCO 2013 Poster discussion
• 7. SGSG-007
  早期卵巣癌（pT1/T2）におけるリンパ節郭清の治療的意義に関する後方視的研究
  日本癌治療学会 2008
  
  Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, Tanimoto H, Noma J, Hayase R, Murakami A, Fujimoto H, Kanamori Y, Kitada F, Shitsukawa K, Nagaji M, Minagawa Y, Fujiwara M, Kigawa J
  Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group
  Int J Clin Oncol 2012: 17
• 8. SGSG-008/TGCU Intergroup study
  再発危険因子を有する子宮部非扁平上皮癌Ib-II期に対する術後補助療法としてのタキサン製剤＋カルボプラチン併用療法の有効性および安全性に関する検討（第II相試験）
  
  Sato S, Shimada M, Ohta T, Kojimahara T, Tokunaga H, Takano T, Yamaguchi S, Tanabe H, Nishio S, Kigawa J.
  Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.
  Int J Gynecol Cancer 2016: 21; 561-567.
• 9．SGSG-009

  Comparison of adjyvant chemotherapy and radiation in patients with cervical adenocarcinoma after radical surgery
  ASCO 2008 Proc Am Soc Clin Oncol 2008: 26; 306s (#5559)
  
  Shimada M, Nishimura R, Hatae M, Hiura M, Takehara K, Tase T, Yamada H, Kurachi H, Sugiyama T, Kigawa J.
  Comparison of adjyvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/TGCU Intergroup surveillance
  Eur J Gynaecol Oncol 2013; 34(5): 425-8
  
  

  
• 10．SGSG-010

  Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjyuvant radiotherapy after radical surgery: SGSG/TGCU Intergroup Survey
  ASCO 2009 Proc Am Soc Clin Oncol 2009: 27; 298s (#5585)
  
  Shimada M, Nishimura R, Nogawa T, Hatae M, Takehara K, Yamada H, Kurachi H, Yokoyama Y, Sugiyama T, Kigawa J.
  Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjyuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance
  Mol Clin Oncol 2013; 1(4): 780-784.

  
• 11．SGSG-012
  再発子宮体癌におけるプラチナfree期間が化学療法の効果に及ぼす影響の後方視的検討
  
  Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-014 study.
  Nagao S, et al.
  IGCS 2012
  
  Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T, Tanioka M, Fujiwara K, Suzuki M, Kigawa J.
  Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study.
  Gynecol Oncol. 2013; 131(3): 567-573
• 13．SGSG-013
  Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma.
  
  Tanioka M, Yamaguchi Sato S, Nagao S, Takehara K, Nishimura M, Sudo T, Morita S, Minami H, Negoro S, Shimada M, Kigawa J, Fujiwara K.
  ASCO, Chicago, poster discussion, 2013.
  

もどる  | ページのトップへ